VANCOUVER, British Columbia, May 17, 2021 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) announces it has received positive feedback from the U.S. Food and Drug Administration (FDA) regarding its plans to investigate AP-188 (“N,N-Dimethyltryptamine” or “DMT”), a known psychedelic compound that is part of the tryptamine…


Previous articleMindMed Receives FDA Type C Meeting Response for Project Lucy Phase 2b Clinical Trial
Next articleIntelGenx Announces Initial Closing of atai Investment